A fundamental role for hippocampal parvalbumin in the dopamine hyperfunction associated with schizophrenia

Schizophrenia Research

Volumn 157, Issue 1-3, 2014, Pages 238-243

  Boley, Angela M ^a   Perez, Stephanie M ^a   Lodge, Daniel J ^a  

^a University of Texas Health Science Center   (United States)

Author keywords

Dopamine; Hippocampus; Parvalbumin; Schizophrenia

Indexed keywords

AMPHETAMINE; DOPAMINE; MESSENGER RNA; PARVALBUMIN; SHORT HAIRPIN RNA; CENTRAL STIMULANT AGENT; SMALL INTERFERING RNA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL POPULATION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOWNSTREAM PROCESSING; HIPPOCAMPUS; LOCOMOTION; MALE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; VENTRAL HIPPOCAMPUS; ACTION POTENTIAL; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENE SILENCING; GENE VECTOR; GENETICS; IMMUNOHISTOCHEMISTRY; LENTIVIRINAE; METABOLISM; MICROELECTRODE; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VENTRAL TEGMENTUM;

ACTION POTENTIALS; AMPHETAMINE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; MALE; MICROELECTRODES; MOTOR ACTIVITY; PARVALBUMINS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; RNA, SMALL INTERFERING; SCHIZOPHRENIA; VENTRAL TEGMENTAL AREA;

EID: 84904119491     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.05.005     Document Type: Article

References (49)

1. Abdul-Monim Z., Neill J.C., Reynolds G.P. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J. Psychopharmacol. 2007, 21(2):198-205.
2. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol. 2004, 7(Suppl. 1):S1-S5.
3. Agid O., Shapira B., Zislin J., Ritsner M., Hanin B., Murad H., Troudart T., Bloch M., Heresco-Levy U., Lerer B. Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major depression, bipolar disorder and schizophrenia. Mol. Psychiatry 1999, 4(2):163-172.
4. Behrens M.M., Ali S.S., Dao D.N., Lucero J., Shekhtman G., Quick K.L., Dugan L.L. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 2007, 318(5856):1645-1647.
5. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., Quinlan E.M., Nakazawa K. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat. Neurosci. 2010, 13(1):76-83.
6. Benes F.M., Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001, 25(1):1-27.
7. Bhugra D. The global prevalence of schizophrenia. PLoS Med. 2005, 2(5):e151. (quiz e175).
8. Chen L., Perez S.M., Lodge D.J. An augmented dopamine system function is present prior to puberty in the methylazoxymethanol acetate rodent model of schizophrenia. Dev. Neurobiol. 2014, (Epub ahead of print), http://dx.doi.org/10.1002/dneu.22172.
9. Cunningham M.O., Hunt J., Middleton S., LeBeau F.E., Gillies M.J., Davies C.H., Maycox P.R., Whittington M.A., Racca C. Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness. J. Neurosci. 2006, 26(10):2767-2776.
10. Figueredo-Cardenas G., Harris C.L., Anderson K.D., Reiner A. Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types. Exp. Neurol. 1998, 149(2):356-372.
11. Francois J., Ferrandon A., Koning E., Angst M.J., Sandner G., Nehlig A. Selective reorganization of GABAergic transmission in neonatal ventral hippocampal-lesioned rats. Int. J. Neuropsychopharmacol. 2009, 12(8):1097-1110.
12. Goldman-Rakic P.S. Cellular basis of working memory. Neuron 1995, 14(3):477-485.
13. Gonzalez-Burgos G., Lewis D.A. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr. Bull. 2012, 38(5):950-957.
14. Grace A.A. Developmental dysregulation of the dopamine system and the pathophysiology of schizophrenia. Neurodevelopment and Schizophrenia 2004, 273-294. Cambridge University Press, Cambridge, UK. M.S. Keshavan, J.L. Kennedy, R.M. Murray (Eds.).
15. Grace A.A., Bunney B.S. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons-1. Identification and characterization. Neuroscience 1983, 10(2):301-315.
16. Grace A.A., Floresco S.B., Goto Y., Lodge D.J. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci. 2007, 30(5):220-227.
17. Harte M.K., Powell S.B., Swerdlow N.R., Geyer M.A., Reynolds G.P. Deficits in parvalbumin and calbindin immunoreactive cells in the hippocampus of isolation reared rats. J. Neural Transm. 2007, 114(7):893-898.
18. Hashimoto T., Volk D.W., Eggan S.M., Mirnics K., Pierri J.N., Sun Z., Sampson A.R., Lewis D.A. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 2003, 23(15):6315-6326.
19. Heckers S. The hippocampus in schizophrenia. Am. J. Psychiatr. 2004, 161(11):2138-2139.
20. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35(3):549-562.
21. Howes O.D., Kambeitz J., Kim E., Stahl D., Slifstein M., Abi-Dargham A., Kapur S. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch. Gen. Psychiatry 2012, 69(8):776-786.
22. Hyland B.I., Reynolds J.N.J., Hay J., Perk C.G., Miller R. Firing modes of midbrain dopamine cells in the freely moving rat. Neuroscience 2002, 114(2):475-492.
23. Janowsky D.S., el-Yousel M.K., Davis J.M., Sekerke H.J. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch. Gen. Psychiatry 1973, 28(2):185-191.
24. Kawaguchi Y., Hama K. Fast-spiking non-pyramidal cells in the hippocampal CA3 region, dentate gyrus and subiculum of rats. Brain Res. 1987, 425(2):351-355.
25. Konradi C., Yang C.K., Zimmerman E.I., Lohmann K.M., Gresch P., Pantazopoulos H., Berretta S., Heckers S. Hippocampal interneurons are abnormal in schizophrenia. Schizophr. Res. 2011, 131(1-3):165-173.
26. Kraguljac N.V., White D.M., Reid M.A., Lahti A.C. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 2013, 70(12):1294-1302.
27. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 2005, 6(4):312-324.
28. Lewis D.A., Curley A.A., Glausier J.R., Volk D.W. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012, 35(1):57-67.
29. Lodge D.J., Grace A.A. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J. Neurosci. 2007, 27:11424-11430.
30. Lodge D.J., Grace A.A. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav. Brain Res. 2009, 7(204(2)):306-312.
31. Lodge D.J., Grace A.A. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol. Sci. 2011, 32(9):507-513.
32. Lodge D.J., Behrens M.M., Grace A.A. A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J. Neurosci. 2009, 29(8):2344-2354.
33. Malaspina D., Storer S., Furman V., Esser P., Printz D., Berman A., Lignelli A., Gorman J., Van Heertum R. SPECT study of visual fixation in schizophrenia and comparison subjects. Biol. Psychiatry 1999, 46(1):89-93.
34. Medoff D.R., Holcomb H.H., Lahti A.C., Tamminga C.A. Probing the human hippocampus using rCBF: contrasts in schizophrenia. Hippocampus 2001, 11(5):543-550.
35. Moore H., Jentsch J.D., Ghajarnia M., Geyer M.A., Grace A.A. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol. Psychiatry 2006, 60(3):253-264.
36. Pantelis C., Barnes T.R.E., Nelson H.E., Tanner S., Weatherley L., Owen A.M., Robbins T.W. Frontal-striatal cognitive deficits in patients with chronic schizophrenia. Brain 1997, 120(10):1823-1843.
37. Perez S.M., Lodge D.J. Aberrant dopamine D2-like receptor function in a rodent model of schizophrenia. J. Pharmacol. Exp. Ther. 2012, 343(2):288-295.
38. Perez S.M., Lodge D.J. Hippocampal interneuron transplants reverse aberrant dopamine system function and behavior in a rodent model of schizophrenia. Mol. Psychiatry 2013, 18(11):1193-1198.
39. Perez S.M., Shah A., Asher A., Lodge D.J. Hippocampal deep brain stimulation reverses physiological and behavioural deficits in a rodent model of schizophrenia. Int. J. Neuropsychopharmacol. 2013, 16(6):1331-1339.
40. Purcell S.M., Wray N.R., Stone J.L., Visscher P.M., O'Donovan M.C., Sullivan P.F., Ruderfer D.M., McQuillin A., Morris D.W., Oĝdushlaine C.T., Corvin A., Holmans P.A., Oĝdonovan M.C., MacGregor S., Gurling H., Blackwood D.H.R., Craddock N.J., Gill M., Hultman C.M., Kirov G.K., Lichtenstein P., Muir W.J., Owen M.J., Pato C.N., Scolnick E.M., St Clair D., Williams N.M., Georgieva L., Nikolov I., Norton N., Williams H., Toncheva D., Milanova V., Thelander E.F., O'Dushlaine C.T., Kenny E., Quinn E.M., Choudhury K., Datta S., Pimm J., Thirumalai S., Puri V., Krasucki R., Lawrence J., Quested D., Bass N., Crombie C., Fraser G., Leh Kuan S., Walker N., McGhee K.A., Pickard B., Malloy P., MacLean A.W., Van Beck M., Pato M.T., Medeiros H., Middleton F., Carvalho C., Morley C., Fanous A., Conti D., Knowles J.A., Paz Ferreira C., MacEdo A., Helena Azevedo M., Kirby A.N., Ferreira M.A.R., Daly M.J., Chambert K., Kuruvilla F., Gabriel S.B., Ardlie K., Moran J.L., Sklar P. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460(7256):748-752.
41. Saha S., Chant D., Welham J., McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005, 2(5):e141.
42. Sawa A., Snyder S.H. Schizophrenia: diverse approaches to a complex disease. Science 2002, 296(5568):692-695.
43. Schobel S.A., Lewandowski N.M., Corcoran C.M., Moore H., Brown T., Malaspina D., Small S.A. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch. Gen. Psychiatry 2009, 66(9):938-946.
44. Schwaller B., Meyer M., Schiffmann S. 'New' functions for 'old' proteins: the role of the calcium-binding proteins calbindin D-28k, calretinin and parvalbumin, in cerebellar physiology. Studies with knockout mice. Cerebellum 2002, 1(4):241-258.
45. Shah A., Lodge D.J. A loss of hippocampal perineuronal nets produces deficits in dopamine system function: relevance to the positive symptoms of schizophrenia. Transl. Psychiatry 2013, 3:e215.
46. Van Den Bosch L., Schwaller B., Vleminckx V., Meijers B., Stork S., Ruehlicke T., Van Houtte E., Klaassen H., Celio M.R., Missiaen L., Robberecht W., Berchtold M.W. Protective effect of parvalbumin on excitotoxic motor neuron death. Exp. Neurol. 2002, 174(2):150-161.
47. van der Meer M.A., Redish A.D. Theta phase precession in rat ventral striatum links place and reward information. J. Neurosci. 2011, 31(8):2843-2854.
48. Vreugdenhil M., Jefferys J.G., Celio M.R., Schwaller B. Parvalbumin-deficiency facilitates repetitive IPSCs and gamma oscillations in the hippocampus. J. Neurophysiol. 2003, 89(3):1414-1422.
49. Weinberger D.R., Berman K.F., Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatry 1986, 43(2):114-124.